Anlotinib combined with benmelstobart as a chemo-free first-line treatment in advanced esophageal squamous cell carcinoma: an exploratory multicenter, single-arm phase II clinical trial

• Published in: Molecular cancer Vol. 24; no. 1; pp. 175 - 13
• Main Authors: Meng, Xiangrui, Yang, Xiuli, Hong, Yonggui, Wang, Wenkang, Zhang, Zhiye, Xia, Jin, Chen, Yunfang, Zhou, Yue, Lu, Taiying, Song, Min, Shan, Zhengzheng, Wu, Tao, Wu, Weilong, Shen, Ling, Guan, Lulu, Ma, Mingying, Wang, Lisen, Luo, Xi, Xin, Dao, Ma, Yihui, Jiang, Guozhong, Qi, Yu, Jiang, Binghua, Zhang, Daoyu, Hu, Biao, Wu, Xiaoying, Peng, Zuofu, Wang, Feng
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 11.06.2025; BioMed Central; BMC
• Subjects: Adult; Aged; Anlotinib; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Benmelstobart; Biomarkers, Tumor; Cancer; Chemotherapy; Clinical trials; Esophageal cancer; Esophageal Neoplasms - drug therapy; Esophageal Neoplasms - mortality; Esophageal Neoplasms - pathology; Esophageal squamous cell carcinoma; Esophageal Squamous Cell Carcinoma - drug therapy; Esophageal Squamous Cell Carcinoma - genetics; Esophageal Squamous Cell Carcinoma - mortality; Esophageal Squamous Cell Carcinoma - pathology; Female; Humans; Indoles - administration & dosage; Ipilimumab; Male; Middle Aged; Mutation; Neoplasm Staging; Next-generation sequencing; PD-L1; Quinolines - administration & dosage; Squamous cell carcinoma; TP53+/FAT1+/NOTCH3; Treatment Outcome; China; PD-L1; TP53+/FAT1+/NOTCH3; Benmelstobart; Esophageal squamous cell carcinoma; Anlotinib; Next-generation sequencing

No combined antiangiogenic and PD-1/PD-L1 blockade therapy has been investigated as a chemo-free first-line treatment for advanced esophageal squamous cell carcinoma (ESCC). This study evaluates the efficacy and safety of anlotinib combined with benmelstobart as a chemo-free treatment in previously...